Sanofi signed a discovery and development collaboration with AI‑driven Earendil Labs focused on bispecific antibodies for autoimmune and inflammatory diseases, a pact valued up to $2.56 billion. Earendil will apply its AI platform to identify and optimize bispecific candidates; Sanofi will lead development and global commercialization, the partners said. The agreement includes roughly $160 million in upfront and near‑term payments and tiered royalties on net sales. Sanofi framed the deal as part of a broader strategy to combine AI discovery engines with pharma development scale; Earendil highlighted the partnership’s potential to expand its platform to multiple autoimmune targets.